Determination of the effective dose of a novel oral formulation of sarolaner (Simparica™) for the treatment and month-long control of fleas and ticks on dogs  by McTier, Tom L. et al.
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Three  laboratory  studies  were  conducted  to determine  the appropriate  dose  of sarolaner,  a novel  isoxazo-
line, for the  treatment  and  month-long  control  of  infestations  of  ﬂeas  and  ticks  on  dogs.  In  the  ﬁrst  study,
dogs  were  treated  orally  with  sarolaner  suspension  formulations  at 1.25,  2.5 or  5.0  mg/kg,  and  infested
with  Dermacentor  reticulatus,  Rhipicephalus  sanguineus  ticks  and  with  Ctenocephalides  felis  felis  (cat  ﬂea)
prior  to treatment  and  then  weekly  for up  to 8 weeks.  Fleas  and  ticks  were  counted  48  h  after  treatment
and  after  each  subsequent  infestation  at 24  h  for ﬂeas  and  48  h  for  ticks.  The  lowest  dose  of  sarolaner
(1.25  mg/kg)  provided  100%  efﬁcacy  against  ﬂeas  from  treatment  through  Day 35  and  98.4% at  Day  56.
This  dose  of sarolaner  resulted  in 99.7–100%  control  of both  species  of ticks  through  Day  28. In Study  2,
dogs  were  dosed  orally  with  placebo  or sarolaner  suspension  formulations  at 0.625,  1.25  or  2.5 mg/kg
and infested  with  Ixodes  scapularis  prior  to treatment  and weekly  for 6 weeks,  Amblyomma  americanum
(pretreatment  and  Day  26),  Dermacentor  variabilis  (Day  33)  and  A. maculatum  (Day  41).  Ixodes  scapularis
was  the  most  susceptible;  the  lowest  dose  (0.625  mg/kg)  providing  >95%  efﬁcacy  through  Day  43. Efﬁcacy
against  D. variabilis  on Day 35 was  >95%  at 1.25 and  2.5  mg/kg,  whereas  the  0.625  mg/kg  dose  gave  only
61.4%  efﬁcacy.  Amblyomma  spp.  were  the  least  susceptible  ticks;  efﬁcacy  of the 1.25  mg/kg  dose at  Day  28
for A. americanum  was  markedly  lower  (88.5%)  than  achieved  for  D. reticulatus  (100%)  at Day  28  and  also
lower  than  for D.  variabilis  at Day  35 (96.2%).  In Study  3,  dogs  were  dosed  orally  with  placebo  or  sarolaner
in  the proposed  commercial  tablet  (SimparicaTM) at 1.0, 2.0  or 4.0  mg/kg,  and infested  with  A. maculatum,
one  of  the  ticks  determined  to be  dose  limiting,  prior  to treatment  and  then  weekly  for  5 weeks.  All
doses  gave  100%  control  of the existing  infestation.  The  two highest  dosages  resulted  in >93%  control  of
subsequent  challenges  for 5  weeks.  There  was  no  signiﬁcant  improvement  in  efﬁcacy  provided  by  the
4.0  mg/kg  dose  over  the  2.0  mg/kg  dose  (P > 0.05)  at any  time  point.  The  2.0  mg/kg  dose  was  superior  to
the  1.0  mg/kg  on  Day  14  (P = 0.0086)  and  as  efﬁcacy  for 1.0 mg/kg  declined  below  90% at  Day  28,  a single
1  mg/kg  dose  would  not  provide  a full month  of tick control.  Thus,  2.0  mg/kg  was  selected  as  the  sarolaner
dose  rate to  provide  ﬂea  and  tick  control  for  at least  one  month  following  a single  oral  treatment.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
The most common permanent or semi-permanent ectoparasites
ccurring on dogs are ﬂeas, ticks and mites. Ctenocephalides felis
elis, the cat ﬂea, is considered the most important ectoparasite of
ogs and cats (Rust and Dryden, 1997) and is endemic worldwide.
dult ﬂeas are blood feeders, are recognized as a major cause of
∗ Corresponding author.
E-mail address: tom.mctier@Zoetis.com (M.R. Myers).
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304-4017/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
allergic skin disease in dogs, and when present in sufﬁcient num-
bers are capable of causing anemia (Krämer and Mencke, 2001).
They are intermediate hosts for the dog tapeworm, Dipylidium can-
inum, and can transmit a number of zoonotic pathogens, including
Bartonella henselae, the causative agent for cat scratch fever, as well
as other zoonotic Bartonellas, such as B. clarrigeae and B. koehlerae
(Chomel and Kasten, 2010).Tick infestations can range from an occasional nuisance to a
continuous infestation and can cause serious, even life-threatening
disease (Dryden and Payne, 2004). During feeding, large amounts
of blood are taken up by ticks; excess water is removed and
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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eturned to the host in the form of saliva, which contains a number
f pharmacologically active substances, including anticoagulants
nd immunomodulators, with the components varying between
pecies. Tick-borne pathogens are normally passed to their next
ost in saliva and some species excrete toxins within their saliva
Needham and Teel, 1991). In severe infestations, tick numbers may
e high enough to cause anemia due to physical blood loss through
heir feeding. Ticks are responsible for the transmission of a num-
er of pathogens, some dog-speciﬁc, and others zoonotic. Babesia
anis and Ehrlichia canis are both primarily dog-speciﬁc infections,
he former primarily transmitted by Dermacentor spp. (D. variabilis,
merican Dog tick and D. reticulatus,  Ornate Cow tick) and the
atter by the Brown Dog tick, Rhipicephalus sanguineus (Chomel,
011; Dantas-Torres et al., 2012). Zoonotic infections include Lyme
isease, caused by Borrelia burgdorferi, and human granulocytic
naplasmosis (HGA), caused by Anaplasma phagocytophilum, which
re transmitted by Ixodes spp., and Rocky Mountain Spotted Fever,
aused by Rickettsia rickettsii, which is transmitted primarily by
icks in the genera Amblyomma, Dermacentor, Ixodes (Dryden and
ayne, 2004; Chomel, 2011) and Rhipicephalus (Demma  et al., 2005).
mblyomma americanum, the Lone Star tick, and A. maculatum, the
ulf Coast tick, have been determined to harbor a number of other
rlichia, Borrelia and Rickettsia spp. (Mixon et al., 2006; Jiang et al.,
012; Moncayo et al., 2010; Nicholson et al., 2009; Paddock et al.,
010).
Control of ﬂeas and ticks is primarily based on the use of parasiti-
ides, and until recently convenient on-animal treatments applied
s spot-on or collar applications have been the standard accepted
ethod (Dryden and Payne, 2004; Rust, 2005). The most widely
sed products include compounds with efﬁcacy against ﬂeas and
icks, as well as speciﬁc insecticides or acaricides. Most have direct
nsecticidal/acaricidal activity and control the parasites on the ani-
al. In addition, there are products such as insect growth regulators
hat may  be orally dosed or applied to the pet and control ﬂeas
y disrupting the off-host life stages (eggs and larvae), and others
hat may  be used for environmental applications. Despite the vari-
ty of available products and application methods, both ﬂeas and
icks remain an ongoing problem for many pet owners. Formula-
ions of spinosad (for ﬂeas only) and more recently, isoxazoline
nsecticide/acaricides have been introduced that provide control
f these ectoparasites for a month or more after a single oral
ose (Robertson-Plouch et al., 2008; Rohdich et al., 2014; Shoop
t al., 2014). There are obvious advantages to orally administered
roducts, which remove environmental/user exposure concerns
hat may  accompany topically applied products. In addition, oral
roducts are not affected by bathing/water exposure as are some
opically administered products, thus ensuring a more uniform per-
ormance during the treatment period.
Sarolaner is a novel isoxazoline with potent activity against ﬂeas
nd ticks that was developed speciﬁcally for companion animals
McTier et al., 2016). Here we report studies conducted to deter-
ine the appropriate dose rate of an oral formulation of sarolaner
SimparicaTM, Zoetis) given as a single dose to dogs to provide treat-
ent of existing infestations and at least one month control of ﬂeas
nd ticks.
. Materials and methods
Three studies were conducted to: 1) compare the relative sus-
eptibilities of ﬂeas and ticks; 2) determine which of the common
icks found on dogs in the US was the least susceptible and; 3)
dentify the minimum dose required to treat and control the least
ensitive parasite (s) for at least one month following a single treat-
ent.sitology 222 (2016) 12–17 13
Study 1 was conducted in South Africa and Studies 2 and 3 were
conducted in the USA. The studies were conducted in accordance
with the World Association for the Advancement of Veterinary
Parasitology (WAAVP) guidelines for evaluating the efﬁcacy of par-
asiticides for the treatment, prevention and control of ﬂea and tick
infestation on dogs and cats (Marchiondo et al., 2013). Study 3
additionally complied with Good Clinical Practices, (VICH guideline
GL9) (EMEA, 2000). Study protocols were reviewed and approved
by the ClinVet and/or Zoetis Institutional Animal Care and Use
Committee (s). Masking of all studies was assured through the
separation of functions. All personnel conducting observations or
animal care, or performing infestations and counts were masked to
treatment allocation.
2.1. Animals
Individually identiﬁed, adult, purpose-bred Beagles ≥8 months
of age and ≤ 20 kg were used in each study. The dogs had not been
treated with an ectoparasiticide for at least 60 days and were in
good health at the time of treatment. Dogs were housed individ-
ually in indoor runs that conformed to accepted animal welfare
guidelines. Dogs were fed an appropriate maintenance ration of a
commercial dry canine feed for the duration of the study. Water
was available ad libitum. Study 1 included 48 dogs (24 male and 24
female), Study 2 used 32 male dogs and Study 3 had 32 dogs (15
male, 17 female).
2.2. Experimental design and methods
General methods: Day 0 represents the day that dogs received
the study treatment. Dogs were acclimated to the study conditions
for at least 14 days prior to treatment. The dogs were observed for
general health at least once daily throughout the studies. A physical
exam was performed on each dog by a veterinarian to determine
health and suitability prior to inclusion in the study. For infestations
in Studies 1 and 2, approximately 100 cat ﬂeas (C. felis felis, ∼1:1 sex
ratio) and/or approximately 50 ticks (∼1:1 sex ratio) of each species
to be assessed were applied directly to a site proximal or adjacent
to the shoulder blades and allowed to crawl into the hair coat. In
study 3, dogs were sedated prior to tick infestation and conﬁned in
shipping crates for approximately 6 h to reduce animal movement
and enhance tick attachment. Forty eight hours after treatment and
each tick infestation and/or 24 h after each ﬂea infestation, every
dog was thoroughly examined and combed to remove and count
ﬂeas and ticks. Flea and tick counts were performed by personnel
trained in the standard procedures in use at the test facility. Protec-
tive gloves and clothing were changed between dogs, and personnel
conducting parasite counts or other observations were unaware of
treatment assignments.
Study 1: On Day–7, each dog was  infested with brown dog ticks
(R. sanguineus). On Day–5, the ticks on each dog were removed and
counted; dogs were ranked by descending tick count into eight
blocks of six, and randomly allocated within blocks to six treat-
ment groups. On Day–2, the dogs were weighed and infested with
R. sanguineus and Dermacentor reticulatus ticks. On Day–1, the dogs
were infested with ﬂeas.
On Day 0, the eight animals in each group were treated via oral
gavage at 0.5 mL/kg body weight with one of the following: placebo;
sarolaner suspension (10 mg/mL) to provide a dose of 5 mg/kg;
sarolaner suspension (5 mg/mL) to provide a dose of 2.5 mg/kg;
sarolaner suspension (2.5 mg/mL) to provide a dose of 1.25 mg/kg;
another isoxazoline analog suspension (5 mg/mL) to provide a dose
of 2.5 mg/kg (results not provided) or sarolaner solution (5 mg/mL)
to provide a dose of 2.5 mg/kg. The results for the latter experi-
mental treatment are reported in McTier et al. (2016). Dogs were
observed for general health and any reaction to treatment approx-
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mately 1, 3 and 6 h after treatment on Day 0, then once daily for
he remainder of the study.
On Day 2, each dog was examined and combed to count and
emove ﬂeas and ticks. Subsequently, all animals were infested
ith R. sanguineus and D. reticulatus on Days 5, 12, 19, 25 and
3, and with ﬂeas on Days 6, 13, 20, 26 and 34. The dogs in the
lacebo group and the group treated with sarolaner at 1.25 mg/kg
ere additionally infested with these ticks on Days 41 and 55 and
ith ﬂeas on Days 42 and 56. All dogs were examined, combed and
arasite counted on Days 7, 14, 21, 27 and 35; placebo dogs and
ogs treated at 1.25 mg/kg were also counted on Days 43 and 56.
For the counts, all dogs were ﬁrst examined visually, and any
icks detected were removed using forceps. Ticks were examined
o determine their viability. Any tick able to move in a coordinated
anner was considered live. The dogs were then thoroughly ﬂea
ombed to count and remove ﬂeas and any remaining ticks. Fleas
ble to stand up right and/or move in a coordinated manner were
onsidered live. Commercial ﬁne-toothed ﬂea combs were used.
ogs were systemically combed using repeated strokes initially
hile standing starting from the head, then proceeding caudally
long the dorsum. The dog was then turned on each side and then
n its back for combing of the sides and ventral surfaces. Dogs were
epeatedly combed until no ﬂeas were recovered for about 5 min.
ach animal was examined for a minimum of 10 min.
Study 2: On Day–9, each dog was infested with I. scapularis.  On
ay–7, the ticks on each dog were removed and counted, the dogs
anked by descending tick count into eight blocks of four, and ran-
omly allocated within blocks to four treatment groups. On Day–2,
he dogs were weighed and infested with I. scapularis and A. amer-
canum ticks.
On Day 0, the eight animals in each group were treated via
ral gavage at 0.5 mL/kg body weight with one of the follow-
ng: placebo; sarolaner suspension (5 mg/mL) to provide a dose
f 2.5 mg/kg; sarolaner suspension (2.5 mg/mL) to provide a dose
f 1.25 mg/kg; or sarolaner suspension (1.25 mg/mL) to provide a
ose of 0.625 mg/kg. Dogs were observed for general health and any
eaction to treatment approximately 1, 3 and 6 h after treatment on
ay 0, then once daily for the remainder of the study.
On Day 2, each dog was examined and combed to remove and
ount ticks (as described above). Subsequently, all animals were
nfested with I. scapularis on Days 5, 12, 19, 26, 33 and 41, and
dditionally with A. americanum on Day 26, D. variabilis on Day 33
nd A. maculatum on Day 41. All dogs were examined and combed
nd live parasites were counted on Days 7, 14, 21, 28, 35 and 43.
Study 3: On Day–9, each dog was infested with A. maculatum. On
ay–7, the ticks on each dog were removed and counted, the dogs
anked by descending tick count into eight blocks of four, and ran-
omly allocated within blocks to four treatment groups. On Day–2,
he dogs were weighed and infested with A. maculatum.
On Day 0, the 8 animals in each group were treated with one of
he following tablet formulations: placebo; sarolaner at 1.0 mg/kg;
arolaner at 2.0 mg/kg; or sarolaner at 4.0 mg/kg. Tablets were indi-
idually shaved and/or sanded to deliver the appropriate dosage for
he dog’s body weight. Tablets were placed at the back of the tongue
nd the dog was  encouraged to swallow. Food was  offered prior to
nd after dosing. Dogs were observed for general health and any
eaction to treatment approximately 1, 3 and 6 h after treatment
n Day 0, then at least once daily for the remainder of the study.
On Day 2, each dog was examined and combed to remove and
ount ticks (as described above). Subsequently, all animals were
nfested with A. maculatum on Days 5, 12, 19, 26, and 33. On Days
, 13, 20, 27 and 34, the ticks on each dog were counted in situ and
ot removed (thumb counted) and the numbers of live (attached
nd free) were determined. All dogs were examined, combed and
icks were counted and removed on Days 7, 14, 21, 28 and 35.sitology 222 (2016) 12–17
2.3. Parasites
Study 1: Cat ﬂeas were from a laboratory colony, which was
initiated with ﬂeas originally obtained from Hannover University,
Germany. R. sanguineus ticks were from a laboratory colony, which
was initiated with ticks originally obtained from a colony in France.
The strain had been maintained for 12 generations in the labo-
ratory. D. reticulatus were from a laboratory colony, which was
initiated with ticks originally obtained from a colony in Ireland.
The strain had been maintained for six generations in the labora-
tory and additional wild caught ticks collected in the Netherlands
had been introduced approximately two years prior to the study
conduct.
Study 2: All tick colonies were initiated with wild caught ticks
from Oklahoma and additional ticks collected locally are introduced
into the colonies at least once every two  years.
Study 3: The A. maculatum colony was  initiated with local
wild-caught ticks from Oklahoma in 1991 and additional engorged
females from the ﬁeld had been introduced every two years; the
latest introduction was  approximately one year prior to the study.
2.4. Data analysis
The individual dog was  the experimental unit and the primary
endpoint was  live ﬂea and/or tick count. Flea and tick counts were
transformed by the loge(count + 1) transformation prior to analy-
sis in order to stabilize the variance and normalize the data. Using
the PROC MIXED procedure (SAS 9.2, Cary NC), transformed counts
were analyzed using a mixed linear model for repeated measures.
The model included the ﬁxed effect of treatment, day of study and
the interaction between treatment and day of study. The random
effects included room, block within room, the interaction between
block and treatment within room (animal term) and error. In Stud-
ies 1 and 2, a priori contrasts were used to compare treatment
means to the control at the one-sided signiﬁcance level  = 0.05. In
Study 3, a priori contrasts were used to assess pair wise comparisons
between treatments at each time point. Testing was  two-sided
at the signiﬁcance level  = 0.05. Percent efﬁcacy, relative to the
control group and based on geometric means, was calculated as
follows:
%Efﬁcacy = (Mean Control - Mean Treated)
Mean Control
× 100
3. Results
3.1. Efﬁcacy
Study 1: Placebo-treated animals maintained ﬂea and tick infes-
tations throughout the study (Tables 1–3). Live ﬂea and tick counts
for all sarolaner dose groups were signiﬁcantly lower than the
placebo group (P ≤ 0.0032) on all post-treatment count days.
Sarolaner administered in a suspension formulation at 1.25, 2.5,
or 5.0 mg/kg provided 100% reduction in live ﬂea counts 48 h after
treatment of the existing infestation, and 100% reduction in live
ﬂea counts when evaluated 24 h after each weekly re-infestation
for 35 days (Table 1). The 1.25 mg/kg treatment group had efﬁcacies
of 99.9 and 98.4% on Days 43 and 56, respectively.
Against R. sanguineus,  all sarolaner treatments resulted in 100%
efﬁcacy within 48 h after treatment and 99.5–100% efﬁcacy against
subsequent infestations through Day 28 (Table 2). The higher
doses 2.5 and 5.0 mg/kg gave 100% efﬁcacy at Day 35, while the
1.25 mg/kg dose resulted in 96.7% efﬁcacy on Day 35 and this
declined to 88.1% on Day 56. Similar efﬁcacy to that shown against R.
sanguineus was  seen with all dosages and formulations of sarolaner
T.L. McTier et al. / Veterinary Parasitology 222 (2016) 12–17 15
Table  1
Geometric mean ﬂea counts for placebo and sarolaner-treated dogs and percent
efﬁcacy relative to placebo for dogs treated orally with sarolaner suspension formu-
lations (Study 1).
Count Day Placebo Sarolaner (mg/kg)
1.25 2.5 5.0
2 59.8 0.0* (100) 0.0* (100) 0.0* (100)
7  71.2 0.0* (100) 0.0* (100) 0.0* (100)
14  77.8 0.0* (100) 0.0* (100) 0.0* (100)
21  80.1 0.0* (100) 0.0* (100) 0.0* (100)
28  75.3 0.0* (100) 0.0* (100) 0.0* (100)
35  69.4 0.0* (100) 0.0* (100) 0.0* (100)
43  84.5 0.1* (99.9) – –
56 76.6 1.3* (98.4) – –
P ≤ 0.05. Percent efﬁcacy is given in parentheses.
* Geometric mean counts are signiﬁcantly lower than placebo.
Table 2
Geometric mean Rhipicephalus sanguineus counts for placebo and sarolaner-treated
dogs and percent efﬁcacy relative to placebo for dogs treated orally with sarolaner
suspension formulations (Study 1).
Count Day Placebo Sarolaner (mg/kg)
1.25 2.5 5.0
2 19.3 0.0* (100) 0.0* (100) 0.0* (100)
7  26.0 0.0* (100) 0.0* (100) 0.0* (100)
14  12.7 0.0* (100) 0.0* (100) 0.0* (100)
21  22.3 0.0* (100) 0.1* (99.6) 0.0* (100)
28  17.1 0.0* (100) 0.1* (99.5) 0.0* (100)
35  25.4 0.8* (96.7) 0.0* (100) 0.0* (100)
43  24.6 0.3* (98.6) – –
56 23.3 2.8* (88.1) – –
P ≤ 0.05. Percent efﬁcacy is given in parentheses.
* Geometric mean counts are signiﬁcantly lower than placebo.
Table 3
Geometric mean Dermacentor reticulatus counts for placebo and sarolaner-treated
dogs and percent efﬁcacy relative to placebo for dogs treated orally with sarolaner
suspension formulations (Study 1).
Count Day Placebo Sarolaner (mg/kg)
1.25 2.5 5.0
2 24.3 0.0* (100) 0.0* (100) 0.0* (100)
7  33.1 0.0* (100) 0.1* (99.7) 0.0* (100)
14  31.9 0.0* (100) 0.0* (100) 0.0* (100)
21  31.0 0.1* (99.7) 0.1* (99.6) 0.0* (100)
28  31.2 0.0* (100) 0.2* (99.4) 0.2* (99.4)
35  25.7 0.5* (98.2) 0.2* (99.3) 0.0* (100)
43  31.5 0.4* (98.6) – –
56  29.4 15.4* (47.7) – –
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Table 4
Geometric mean Ixodes scapularis counts for placebo and sarolaner-treated dogs and
percent efﬁcacy relative to placebo for dogs treated orally with sarolaner suspension
formulations (Study 2).
Count Day Placebo Sarolaner (mg/kg)
0.625 1.25 2.5
2 15.8 0.0* (100) 0.0* (100) 0.0* (100)
7  15.4 0.0* (100) 0.1* (99.4) 0.2* (98.8)
14  17.0 0.3* (98.3) 0.0* (100) 0.1* (99.5)
21  16.0 0.1* (99.4) 0.0* (100) 0.0* (100)
28  16.3 0.3* (98.2) 0.0* (100) 0.0* (100)
35  14.2 0.5* (96.6) 0.0* (100) 0.0* (100)
43  16.2 0.8* (95.0) 0.1* (99.1) 0.0* (100)
P ≤ 0.05. Percent efﬁcacy is given in parentheses.
* Geometric mean counts are signiﬁcantly lower than placebo.
Table 5
Geometric mean Amblyomma americanum (A.a), Dermacentor variabilis (D.v), and
Amblyomma maculatum (A.m) counts for placebo and sarolaner-treated dogs and
percent efﬁcacy relative to placebo for dogs treated orally with sarolaner suspension
formulations (Study 2).
Count Day Tick Placebo Sarolaner (mg/kg)
0.625 1.25 2.5
2 A.a 3.5 0.2* (94.5) 0.4* (89.5) 0.1* (97.4)
28  A.a 3.2 1.1* (66.8) 0.4* (88.5) 0.2* (94.0)
35  D.v 28.3 10.9* (61.4) 1.1* (96.2) 0.1* (99.7)
43  A.m 22.8 15.4 (32.6) 7.2* (68.3) 0.9* (96.1)
P ≤ 0.05. Percent efﬁcacy is given in parentheses.
* Geometric mean counts are signiﬁcantly lower than placebo.
Table 6
Geometric mean Amblyomma maculatum thumb counts at 24 h after infestation for
placebo and sarolaner-treated dogs and percent efﬁcacy relative to placebo for dogs
treated orally with sarolaner tablet formulation (Study 3).
Count Day Placebo Sarolaner (mg/kg)
1.0 2.0 4.0
6 22.6a 2.4b (89.5) 0.4c (98.4) 1.7bc (92.4)
13  29.6a 10.0b (66.2) 2.3c (92.3) 1.5c (94.8)
20  24.5a 7.5b (69.2) 4.9b (79.9) 2.1c (91.6)
27  20.3a 15.4ab (24.4) 12.1b (40.7) 6.8c (66.3)
34  20.9a 14.3ab (31.9) 11.6b (44.7) 4.8c (76.9)
P > 0.05. Percent efﬁcacy is given in parentheses. ≤ 0.05. Percent efﬁcacy is given in parentheses.
* Geometric mean counts are signiﬁcantly lower than placebo.
gainst D. reticulatus with efﬁcacy maintained at 98.2–100% for
3 days (Table 3).
Study 2: Placebo-treated animals maintained tick infestations
ollowing each challenge, though recoveries of A. americanum
approx. 3/dog) were markedly lower than the other three tick
pecies (approx. 14–28 per dog) (Tables 4 and 5). Live tick counts for
ll sarolaner dose groups were signiﬁcantly lower than the placebo
roup (P ≤ 0.0279) on all post-treatment count days for all tick
pecies except for the 0.625 mg/kg group against A. maculatum on
ay 43 (P = 0.2827).
Against an existing infestation of I. scapularis,  sarolaner at all
oses provided 100% reduction in live tick counts 48 h after treat-
ent (Table 4). The two highest doses 1.25 and 2.5 mg/kg resultedn ≥98.8% efﬁcacy against subsequent re-infestations up to Day 43.
ersistent efﬁcacy for the 0.625 mg/kg dose was slightly lower at
8.2, 96.6 and 95.0% on Days 28, 35 and 43, respectively.Geometric mean counts with the same superscript within rows are not signiﬁcantly
different.
For A. americanum, Day 2 efﬁcacy versus the existing infestation
ranged from 89.5 to 97.4% (Table 5). At Day 28, efﬁcacies for the
0.625, 1.25 and 2.5 mg/kg doses were 66.8, 88.5 and 94.0%, respec-
tively. For D. variabilis on Day 35, the respective efﬁcacies were
61.4, 96.2 and 99.7%, and for A. maculatum (Day 43) these were 32.6,
68.3 and 96.1%, respectively. Generally, efﬁcacy against these three
species was  markedly lower than that for I. scapularis assessed at
the same dose and time point (Tables 4 and 5).
Study 3: Placebo-treated animals maintained A. maculatum
infestations following each challenge, with mean recoveries of
20.3–29.6 ticks per dog at 24 h thumb counts (Table 6) and
15.2–27.6 ticks per dog at the 48 h comb counts (Table 7). Live
tick counts for all sarolaner dose groups were signiﬁcantly lower
than the placebo group (P ≤ 0.0290) on all post-treatment count
days except for the 1.0 mg/kg group thumb counts on Days 27
(P = 0.1355) and 34 (P = 0.1174).
Tick counts determined by thumb counts showed that high efﬁ-
cacy was  achievable within 24 h of infestation but this was  variable.
The 2 and 4 mg/kg dosages resulted in >90% reduction for 2 and 3
weeks post-treatment, respectively (Table 6).
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Table 7
Geometric mean Amblyomma maculatum counts at 48 h after treatment and infesta-
tion for placebo and sarolaner-treated dogs and percent efﬁcacy relative to placebo
for dogs treated orally with sarolaner tablet formulation (Study 3).
Count Day Placebo Sarolaner (mg/kg)
1.0 2.0 4.0
2 15.2a 0.0b (100) 0.0b (100) 0.0b (100)
7  24.6a 0.3b (98.8) 0.2b (99.2) 0.0b (100)
14  27.6a 0.6b (97.7) 0.0c (100) 0.1c (99.6)
21  23.3a 0.0b (100) 0.4b (98.4) 0.4b (98.2)
28  20.9a 2.2b (89.5) 1.2bc (94.2) 0.2c (99.1)
35  20.7a 3.4b (83.4) 1.4bc (93.2) 0.4c (98.6)
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y > 0.05. Percent efﬁcacy is given in parentheses.
eometric mean counts with the same superscript within rows are not signiﬁcantly
ifferent.
All three sarolaner dosages resulted in 100% efﬁcacy against the
xisting infestation at 48 h. For post-treatment infestations, live tick
ounts for the 1.0 mg/kg dose were not signiﬁcantly different to
hose for the 2.0 mg/kg dose (P > 0.05) at all time-points except Day
4, and counts were not different for the 2.0 and 4.0 mg/kg dosages
n any day. The 1.0 mg/kg dose only provided >90% efﬁcacy through
ay 21 and control declined to <90% thereafter. Both the 2.0 and
.0 mg/kg doses provided >93% control through Day 35 (Table 7).
.2. Health observations
There were no adverse health events related to treatment with
arolaner noted in any study.
. Discussion
In the ﬁrst study, sarolaner at all doses, was highly effective for
he treatment and control of ﬂea and tick infestations on dogs for
t least one month. Efﬁcacy against ﬂeas was 100% from treatment
hrough Day 35 and >95% through Day 56. Ticks were less suscepti-
le, though treatment at the lowest dose resulted in ∼100% control
f both species for at least 4 weeks. In this study, D. reticulatus was
he least sensitive species, followed by R. sanguineus and then by
eas, and the lowest dose of 1.25 mg  sarolaner/kg provided treat-
ent and control ( > 96%) of all three parasite species for at least
ne month after treatment.
The second study titrated sarolaner doses from 0.625 to
.5 mg/kg against I. scapularis and included point evaluations
gainst three other tick species. Ixodes scapularis was highly suscep-
ible, with the lowest dose of sarolaner providing 100% reduction
or the existing infestation on Day 2 and >95% efﬁcacy through Day
3. On Day 35 efﬁcacy against D. variabilis was >96% for the 1.25
nd 2.5 mg/kg dosages, but the 0.625 mg/kg dose only resulted in
1.4% reduction, which was similar to that achieved for D. reticula-
us in the previous study. Point tests with Amblyomma spp. on Days
, 28, and 43 indicated that this genus was the least susceptible
f the ticks tested, as no dose tested resulted in 100% control of an
xisting infestation of A. americanum, and efﬁcacy at Day 28 for this
pecies was markedly lower than that achieved for D. reticulatus at
he same dose rates in the previous study. Also, the Day 28 efﬁ-
acy at all dose rates was generally lower for A. americanum than
or D. variabilis at Day 35. Efﬁcacy versus A. maculatum at Day 43
as similarly low with the two lower doses (0.625 and 1.25 mg/kg)
esulting in <70% control.
Collectively, these two studies indicated that ticks were less sus-
eptible than ﬂeas to sarolaner and that Amblyomma spp. were the
east sensitive ticks. In Study 2, a dose of 1.25 mg/kg resulted in <90%
ontrol of the existing infestation of A. americanum and against
ost-treatment challenge on Day 28, while a dose of 2.5 mg/kg
ielded >94% control of an existing infestation of Amblyomma spp.sitology 222 (2016) 12–17
and post-treatment challenges for at least 43 days. This suggested
that a minimum dose of between 1.25–2.5 mg/kg would be needed
to ensure effective treatment and control of ﬂeas and ticks for a
month following a single treatment. Based on the markedly better
tick recovery from placebo dogs for A. maculatum (22.8 ticks/dog)
versus A. americanum (∼3.5 ticks/dog) and the similar efﬁcacy, A.
maculatum was selected as the species for dose determination in
Study 3.
All dose levels of sarolaner (1.0, 2.0 and 4.0 mg/kg) provided
100% efﬁcacy against an existing infestation of A. maculatum within
48 h post-treatment in Study 3. The lowest dose (1.0 mg/kg) pro-
vided >90% reduction of subsequent infestations at 48 h through
Day 21 but efﬁcacy declined to <90% thereafter, while both the
2.0 and 4.0 mg/kg doses resulted in >90% efﬁcacy through Day 35.
There was no signiﬁcant improvement in efﬁcacy provided by the
4.0 mg/kg dose over the 2.0 mg/kg dose (P > 0.05) at any time point.
The 2.0 mg/kg dose was  not signiﬁcantly superior to the 1.0 mg/kg
on any day except Day 14 (P = 0.0085), however, efﬁcacy for the
1 mg/kg dose declined below 90% at Day 28, indicating that a single
dose was  unlikely to provide optimal tick control for a full month.
Thus, the 2.0 mg/kg dose rate was selected as the minimum dose
rate to provide ﬂea and tick control for at least one month following
a single oral treatment.
5. Conclusions
These studies demonstrated that a dose rate of 2.0 mg
sarolaner/kg provided effective treatment and control of ﬂeas and
ticks on dogs for one month after a single oral treatment.
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